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elimination strategies and policies
ACTwatch Group1*, Sochea Phok2* and Dysoley Lek3,4

Abstract
Background: Understanding Cambodia’s anti-malarial and diagnostic landscape in 2015 is critical for informing and
monitoring strategies and policies as Cambodia moves forward with national efforts to eliminate malaria. The aim of
this paper is to present timely and key findings on the public and private sector anti-malarial and diagnostic landscape in Cambodia. This evidence can serve as a baseline benchmark for guiding implementation of national strategies as well as other regional initiatives to address malaria elimination activities.
Methods: From August 17th to October 1st, 2015, a cross sectional, nationally-representative malaria outlet survey
was conducted in Cambodia. A census of all public and private outlets with potential to distribute malaria testing
and/or treatment was conducted among 180 communes. An audit was completed for all anti-malarials, malaria rapid
diagnostic tests (RDT) and microscopy.
Results: A total of 26,664 outlets were screened, and 1303 outlets were eligible and interviewed. Among all screened
outlets in the public sector, 75.9% of public health facilities and 67.7% of community health workers stocked both
malaria diagnostic testing and a first-line artemisinin-based combination therapy (ACT). Among anti-malarial-stocking
private sector outlets, 64.7% had malaria blood testing available, and 70.9% were stocking a first-line ACT. Market
share data illustrate that most of the anti-malarials were sold or distributed through the private sector (58.4%), including itinerant drug vendors (23.4%). First-line ACT accounted for the majority of the market share across the public and
private sectors (90.3%). Among private sector outlets stocking any anti-malarial, the proportion of outlets with a firstline ACT or RDT was higher among outlets that had reportedly received one or more forms of ‘support’ (e.g. reportedly
received training in the previous year on malaria diagnosis [RDT and/or microscopy] and/or the national treatment
guidelines for malaria) compared to outlets that did not report receiving any support (ACT: 82.1 and 60.6%, respectively; RDT: 78.2 and 64.0%, respectively).
Conclusion: The results point to high availability and distribution of first-line ACT and widespread availability of
malaria diagnosis, especially in the public sector. This suggests that there is a strong foundation for achieving elimination goals in Cambodia. However, key gaps in terms of availability of malaria commodities for case management must
be addressed, particularly in the private sector where most people seek treatment. Continued engagement with the
private sector will be important to ensure accelerated progress towards malaria elimination.
Keywords: Malaria elimination, Case management, Anti-malarial, ACT, Private sector, Cambodia
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Background
Over the past decade, malaria interventions have made
substantial progress in Cambodia, demonstrated by rapid
declines in the malaria burden since the early 2000s, with
reported cases decreasing by approximately 50% between
2004 and 2014 [1]. However, of Cambodia’s 25 provinces,
21 are still considered to be endemic, and an estimated
48% of the population live in high transmission areas
[2]. Furthermore, there has been a resurgence of malaria
cases between 2014 and 2015, from 44,748 to 56,371, and
resistance to artemisinin-based combination therapy
(ACT) continues to threaten progress towards national
malaria strategies [3]. This situation is all the more pressing given the country’s recent commitment to eliminate
malaria by 2020, as coverage of appropriate case management in the context of malaria elimination strategies will
be critical to achieving this goal [1].
In 2016, Cambodia’s National Centre for Parasitology, Entomology and Malaria Control (CNM) released
the Malaria Elimination Action Framework, 2016–
2020, (MEAF) outlining the country’s strategies and
plans to achieve elimination of Plasmodium falciparum
and multi-drug resistant malaria by 2020 [1]. Several
key objectives are described in the MEAF, including
100% parasitological diagnosis for all suspected cases
and effective, efficacious treatment of all confirmed
uncomplicated malaria cases using first-line ACT: dihydroartemisinin-piperaquine (DHA PPQ) or artesunate–
mefloquine (ASMQ) fixed-dose combination (FDC). For
P. falciparum infections or mixed infections that include
P. falciparum, the MEAF stipulates use of a single lowdose of primaquine. For P. vivax infections, a standard
dose of primaquine for up to 14 days is indicated in order
to prevent relapse. The MEAF stipulates that glucose6-phosphate dehydrogenase (G6PD) testing should be
conducted prior to administering primaquine treatment
for Plasmodium vivax cases.
The MEAF also outlines several key strategies to ensure
readiness of public and private facilities to adhere to the
national treatment guidelines for malaria [1]. Malaria
treatment or referral services will be available at all public
health facilities, licensed private sector providers, trained
village malaria workers (VMW), mobile malaria workers, and military medical services. In the public sector,
the VMW programme, which provides malaria diagnosis and treatment among remote communities through
a community-based health workforce, will be scaled
up. The number of villages with at least one VMW will
almost double, from 2539 currently to 4528 over the
course of the next 5 years. In addition, these communitybased providers will be allowed to administer low dose
primaquine for P. falciparum to reduce malaria transmission and for radical cure of P. vivax. The VMW will
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also receive training on malaria, case management, counseling, and health education.
In the private sector, where most patients in Cambodia seek treatment [4], the strategy outlines the scale-up
of the existing public–private mix (PPM) programme
by mapping all existing providers and registering new
providers. Refresher courses on early malaria diagnosis, treatment, referral, and reporting will be conducted
every 2 years for PPM programme providers. The strategy also specifies that providers that do not qualify for
the PPM programme will not be allowed to provide or
sell anti-malarials or diagnostics. However, efforts will
also be made to identify and select unlicensed private
providers that can be targeted for licensing so that they
can be registered under the PPM programme. Several initiatives will be implemented to enforce the regulation of
private sector service providers through the Department
of Drug and Food (DEF) and the Anti-Economic Crime
Police. Finally, the strategy also stipulates that there will
be increased efforts to ban the import and sale of antimalarial drugs that are not in the national malaria treatment guidelines [1]. This will be implemented by keeping
the DDF updated on the anti-malarial drugs that are not
included in the national malaria treatment guidelines.
These current national strategies outlined in the MEAF
build on the country’s earlier efforts to promote expansion of the public sector and increased regulation of the
private sector [5, 6]. In the public sector, the VMW programme has been a key strategy for increasing access to
malaria commodities among remote rural populations.
By 2014, a decade after it was piloted in 300 villages, the
VMW programme covered over 1600 villages and 130
mobile communities across 17 malaria endemic provinces [1]. Private sector engagement has been in place
since 2002, through national distribution of subsidized
anti-malarials and rapid diagnostic testing (RDT) for private sector providers across the country [6]. In 2008, oral
artemisinin monotherapy was banned, with several hardline strategies in place to enforce the policy [7]. Increased
regulation of the private sector commenced around this
time, to reduce the role of unauthorized private sector
providers, including drug stores and general retailers, in
anti-malarial distribution, while continuing to support
distribution by registered private for-profit health facilities and pharmacies. In 2011, the CNM and the Ministry
of Health (MoH) established the aforementioned PPM
programme to further engage the private sector and provided subsidized commodities, training, and supervision. The PPM programme was subsequently scaled up in
2014, with nearly 1200 licensed private providers enrolled
across 34 operational districts (ODs) out of a total of 45
malaria endemic ODs [1]. Indeed, efforts to date by the
CNM and other implementing partners have been highly
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successful in strengthening and shaping Cambodia’s antimalarial and malaria diagnostic landscape. Supply-side
evidence from 2013 has shown an increase in the widespread distribution of first-line ACT, successful removal
of oral artemisinin monotherapy, a decrease in the number of unregulated outlets stocking anti-malarials, and an
increase in public sector anti-malarial market share and
composition, namely through the VMW programme [5].
Evidence on the role and performance of the public
and private sectors will provide a baseline benchmark
for guiding implementation of national strategies. The
ACTwatch project, implemented since 2008 across a
number of countries by Population Services International
(PSI), provides timely, relevant, and high quality antimalarial market evidence to inform and monitor national
and global policy, strategy, and funding decisions for
improving malaria case management [8, 9]. In 2015, an
ACTwatch survey was implemented in Cambodia. The
evidence generated from this project provides an opportunity to present contemporary market intelligence data
on Cambodia’s anti-malarial and diagnostic landscape as
a means to inform and monitor strategies and policies as
the country moves forward with elimination activities.
The evidence from this survey can also help to frame the
anti-malarial and diagnostic market in the context of the
MEAF strategies, as well as other regional and countryspecific initiatives to accelerate progress towards elimination of malaria. The objectives of this paper are twofold:
(1) to describe contemporary public and private sector
readiness (availability of malaria commodities) and performance (market share) for malaria case management;
and (2) to compare private sector readiness and provider
knowledge between outlets that reportedly received
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supportive interventions (e.g. access to malaria commodities, or training) with private outlets that did not receive
these interventions.

Methods
Design and sampling

The study population was defined as all outlets with the
‘potential’ to sell or distribute anti-malarial medicines
and/or provide malaria blood testing. The methodology
of ACTwatch adopts a more inclusive, rather than exclusive, way of determining outlet types for the study, by
including a broad list of outlet types that may or may not
sell or distribute anti-malarial medicines and/or provide
malaria blood testing. While some outlets are expected
to have anti-malarials, other outlets, such as general
retailers, may be theorized to not stock these medicines.
Such outlets are, however, included in the sample as a
means to investigate this theory and to determine if these
outlets do indeed contribute to malaria case management
in a given country. Outlet types that are included in the
sample are determined according to each specific country context. The outlet types that were included in the
Cambodia survey are described in Table 1. Outlets that
did not serve the general public (e.g. military facilities)
were excluded from the outlet survey, but military and
police facilities that also served the general public were
included.
In 2014, the World Health Organization (WHO) used
available evidence about artemisinin resistance to define
a 3-tier stratification system for targeting action to
address drug resistance [10]. This tier system replaced
the previous zone stratification used in Cambodia [11].
Areas designated as Tier 1 were prioritized for immediate

Table 1 Outlet types and definitions
Sector and facility type

Definition

Public sector
Public health facilities

Referral hospitals, health centers, former district hospitals, health posts, NGO/mission/faith-based hospitals, NGO/
mission/faith-based clinics, and NGO/mission/faith-based diagnostic laboratories

Community health workers

Community-based volunteers, either Village Malaria Workers, Mobile Malaria Workers, or Plantation Malaria Workers,
who are equipped with anti-malarial treatment and malaria blood testing

Private sector
Private for-profit health facilities

Private hospitals, clinics, polyclinics, cabinets, health care rooms, and private diagnostic laboratories and would be
expected to have been registered in country

Pharmacies

Regulated by a national regulatory authority and staffed by pharmacists or qualified health practitioners. These
include pharmacies, clinical pharmacies, depot A, and depot B. These may or may not be licensed by a national
regulatory authority

Drug stores

Drug stalls in rural markets or shops that primarily sell medicines. These outlets are not guaranteed to be staffed by
qualified health dispensers or practitioners and are not typically licensed by a national regulatory authority

General retailers

Grocery stores and village shops and are not licensed by a national regulatory authority

Itinerant drug vendors

Mobile providers found primarily in rural areas, typically working within a radius of their home. They are not registered with any national regulatory authority. Some itinerant drug vendors operate with both a fixed location and
a mobile service, while others operate solely through a mobile service.
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multifaceted response to contain or eliminate resistance.
Areas designated as Tier 2 were prioritized for intensified
malaria control to reduce transmission and/or limit the
risk of emergence or spread of resistant parasites. Tier 3
areas had no evidence of artemisinin resistance and limited contact with Tier 1 areas. Malaria control in these
areas focused on vector control, increasing coverage with
confirmatory testing and treatment with quality-assured
ACT [12]. The Cambodia outlet survey was stratified to
deliver estimates for domains according to this tier stratification system, with the first research domain designated
as tier 1 provinces and the second research domain designated as tier 2 provinces.
From a list of all communes in each research domain,
the required number of units was selected with probability proportional to size (PPS). Selection of units with PPS
was completed based on population estimates obtained
from a 2010 Ministry of Planning projection based on
findings from the 2008 national census. The sampling
frames for each tier excluded communes that were
located in non-malaria-endemic areas according to information provided by the CNM.
Within each commune, a census of all outlets with the
potential to sell or distribute anti-malarials and/or provide malaria blood testing was conducted. Outlets were
eligible for a provider interview and malaria product
audit if they met at least one of three study criteria: (1)
one or more anti-malarials reportedly in stock on the day
of the survey; (2) one or more anti-malarials reportedly
in stock within the three months preceding the survey;
and/or (3) malaria RDT in stock or malaria microscopy
available on the day of the survey.
Sample size

Sample size was determined to estimate with precision (±10% points) two key indicators among public
and private outlets: (1) proportion of outlets with firstline anti-malarial treatments available, among outlets
with anti-malarial(s) in stock on the day of the survey;
and (2) proportion of outlets with malaria blood testing
(RDT or microscopy) available, among outlets with antimalarial(s) in stock on the day of the survey or within the
past 3 months. Estimates from the 2013 ACTwatch outlet
survey were used to complete these calculations. A sample size of 80 Tier 1 and 80 Tier 2 communes was anticipated to yield the minimum required numbers of outlets.
Data collection

Standard procedures used by the ACTwatch project
to implement surveys have been described elsewhere
[27]. Interviewers, supervisors, and quality controllers
received training that included an orientation to the study
and questionnaire, classroom training on completing
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anti-malarial and RDT audits, and a field exercise. Following training, data collection was implemented from
August 17th to October 1st, 2015. The outlet survey was
conducted using handheld devices with an Android operating system and electronic forms created using DroidDB
(SYWARE, Inc., Cambridge, MA, USA). The questionnaire was translated from English to Khmer, and translated back into English to resolve any discrepancies prior
to the survey implementation.
A series of screening questions were administered at
all outlets to determine eligibility for the survey. Outlets
where anti-malarial medicines were reportedly sold and/
or malaria blood testing was reportedly available were
invited to participate in the survey. Following informed
consent procedures, an audit of all available anti-malarial
medicines and RDT was conducted. In addition to the
product audit, a series of questions was administered to
the senior-most provider regarding malaria case management knowledge and practices as well as provider training and qualifications and reporting on malaria caseload
data. Up to three visits were made to all outlets to complete the screening process, audit, and provider interview
as needed.
Data analysis

Electronic data were imported to a master dataset using
Microsoft Access (Microsoft Corporation, Redmond,
Washington, USA), and records were triangulated with
questionnaires, field supervisor tracking records, and
daily activity logs completed by interviewers. All data
cleaning and analysis was completed using Stata 12.1
(StataCorp, College Station, TX, USA). Sampling weights
were applied to account for variations in probability of
selection, and standard error estimation accounted for
clustering at the commune level.
Indicators were produced according to ACTwatch
standards that have been implemented across time and
country studies and which have been described in detail
elsewhere [8, 9]. Availability of any anti-malarial was
calculated with a denominator of all screened outlets.
In the public sector, the availability of specific types of
anti-malarials was calculated using the denominator of
all screened outlets, given that anti-malarials should be
available at all public health facilities and community
health workers (CHW) designated as VMW. Availability
of specific anti-malarial categories in the private sector
was calculated using a denominator of private sector outlets stocking any anti-malarial.
The volumes of each anti-malarial that were reportedly distributed in the week prior to the survey, according to provider reports, were standardized into adult
equivalent treatment doses (AETD) to allow for comparisons between medicines, based on WHO treatment
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guidelines for the amount of active ingredient required
to treat an adult weighing 60 kg [13]. These standardized
AETD volumes were then used to calculate market share
for each anti-malarial category. Audited medicines that
were missing information required to calculate AETD
(strength or amount distributed) were excluded from this
indicator.
Private sector outlet support status (the presence or
absence of support) was calculated according to multiple provider self-reported variables. An outlet was
considered as having received any support if the provider reported one or more of the following: (1) outlet
received subsidized anti-malarials and/or malaria RDT;
(2) at least one provider at the outlet received training on
the national treatment guidelines for malaria or malaria
diagnosis within the previous year; (3) outlet received a
supervisory/regulatory visit within the previous year;
and/or (4) outlet reports malaria caseload data to the
government or a non-governmental organization. Support status was very likely to be correlated with outlet
type, given that governmental and non-governmental
organizations target only registered private health facilities and pharmacies for support and do not typically support unauthorized drug stores, general retail outlets, or
itinerant drug vendors. Availability and provider knowledge indicators for supported and non-supported outlets were therefore adjusted for outlet type using logistic
regression to produce adjusted predicted probabilities.
Anti-malarial availability indicators were calculated
among outlets with any anti-malarial in stock on the day
of the survey. Malaria blood testing availability and provider knowledge of first-line treatment indicators were
calculated among outlets with any anti-malarial in stock
on the day of the survey or within the three months prior
to the survey.

stock anti-malarial medicines on the day of the survey or
within the previous three months.
In total, 164 outlets reported distributing an antimalarial during the week prior to the survey, and 427
outlets reported providing or distributing a malaria diagnostic test in the week prior to the survey. Table 2 shows
a detailed breakdown of the screening, eligibility, and
interview results across outlet types and sectors. Provider
characteristics are included in Additional file 1.

Results

Availability in the private sector

Sample description

Table 4 shows a detailed breakdown of availability of any
anti-malarial among all private sector outlets, followed
by availability of malaria blood testing and anti-malarials
among anti-malarial-stocking private sector outlets.
Approximately one-third of screened private for-profit
health facilities (31.0%), one-fifth of pharmacies (20.5%),
and 15.1% of itinerant drug vendors were stocking any
anti-malarial on the day of the survey. Of 23,840 general
retailers screened, only 0.2% were found to be stocking
any anti-malarial.
Among anti-malarial-stocking private sector outlets,
nearly two-thirds had malaria blood testing available
(64.7%); 63.8% were stocking a malaria RDT, while 8.7%
had malaria microscopy available. Availability of malaria
blood testing was highest in private for-profit health
facilities (83.0%) and pharmacies (70.1%). Over half of

A total of 26,664 outlets were screened to assess eligibility
for the outlet survey, and only 51 outlets refused screening or survey participation. Of the outlets screened, 604
(2.3%) were in the public sector, and 26,060 (97.7%) were
in the private sector. A total of 1303 outlets were eligible and interviewed, and only five outlets met eligibility
criteria but did not complete the interview. Of the eligible outlets, 557 (42.7%) were in the public sector, and 746
(57.3%) were in the private sector.
Of the 1303 outlets interviewed, 858 (65.8%) were
stocking at least one anti-malarial on the day of the survey, 1112 (85.3%) were stocking at least one anti-malarial
either on the day of the survey or within the previous
three months, and 191 (14.7%) were stocking a malaria
diagnostic test (either RDT or microscopy) but did not

Availability in the public sector

Table 3 shows a detailed breakdown of malaria blood
testing availability, first-line anti-malarial availability, and
readiness for malaria case management across screened
public sector outlets. Availability of malaria diagnostics
was relatively high in the public sector, with 85.9% of
all public sector outlets stocking either malaria RDT or
microscopy, and this was highest among CHW (87.2%).
Availability of malaria RDT was higher than microscopy,
with 85.8% of public sector outlets stocking malaria RDT
and only 7.2% reporting availability of malaria microscopy. Malaria microscopy was available in only 27.8% of
public health facilities.
Availability of first-line ACT in the public sector was
slightly lower than diagnostic availability, with just under
three-fourths of all public sector outlets (74.7%) stocking any first-line ACT on the day of the survey. Among
these outlets, 100% of the first-line ACT audited was
DHA PPQ, as no outlets were stocking ASMQ FDC. Primaquine was not available in any public sector outlets.
Three-fourths of public health facilities (75.9%) had
both malaria diagnostic testing and a first-line ACT.
Malaria case management readiness was lower among
CHW, with only 67.7% of CHW stocking both malaria
testing and first-line treatment.

0

Eligible but not interviewed
(interview non-participation)

137

140

2

With at least one anti-malarial

With at least one anti-malarial,
or at least one anti-malarial
in the past 3 months

With malaria blood testing, but
no anti-malarials in stock on
the day of the survey or in
the previous 3 months

Number of interviewed outlets

1

Refused

173

142

Screened

Eligible and interviewed

Number of outlets

Public
health
facility

Table 2 Outlet survey sample

13

402

330

1

0

415

430

Community
health workers

n/a

n/a

n/a

0

0

0

1

15

542

467

1

1

557

604

Private not-for- All public
profit facility
sector

90

237

186

1

2

327

668

Private forprofit health
facility

25

74

45

2

1

99

290

Pharmacy

12

34

22

0

1

46

338

Drug
store

0

39

29

1

43

39

23,840

General
retailer

49

186

109

0

3

235

924

Itinerant drug
vendor

176

570

391

4

50

746

26,060

All private
sector

191

1112

858

5

51

1303

26,664

All outlets
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Table 3 Availability of malaria commodities and readiness for case management in the public sector, among all screened
outlets
Public health facility

Community health workers

All public sector

N = 173

N = 430

N = 603

% (95% CI)

% (95% CI)

% (95% CI)

Any malaria blood testing

82.3 (74.9, 87.8)

87.2 (82.7, 90.6)

85.9 (82.1, 89.0)

Malaria microscopy

27.8 (21.0, 35.8)

0.3 (0.1, 1.8)

RDT

81.7 (74.3, 87.4)

87.2 (82.7, 90.6)

85.8 (81.9, 88.9)

Any first-line ACT (DHA PPQ and/or ASMQ FDC)

76.5 (67.8, 83.5)

74.1 (66.2, 80.7)

74.7 (68.3, 80.1)

DHA PPQ

76.5 (67.8, 83.5)

74.1 (66.2, 80.7)

74.7 (68.3, 80.1)

Diagnostics
7.2 (5.3, 9.7)

Anti-malarials

ASMQ FDC

0.0 (–)

0.0 (–)

0.0 (–)

Primaquine

0.0 (–)

0.0 (–)

0.0 (–)

Other non-artemisinin therapy

8.9 (4.9, 15.5)

0.0 (–)

2.2 (1.3, 3.9)

IV/IM artesunate

0.0 (–)

n/a

0.0 (–)

Readiness
Availability of first-line ACT and malaria blood testing

75.9 (67.1, 82.9)

Availability of first-line ACT, blood testing not available

0.7 (0.2, 2.4)

itinerant drug vendors were stocking a diagnostic test
(60.4%).
Among those private sector outlets stocking any antimalarial, 70.9% were stocking a first-line ACT, all of
which was DHA PPQ rather than ASMQ FDC. Private
for-profit health facilities and pharmacies had the highest
availability of a first-line ACT (90.0 and 85.6%, respectively). Availability of a first-line ACT was also moderately high among anti-malarial-stocking itinerant drug
vendors (62.8%). Fewer than half of anti-malarial-stocking drug stores (47.9%) and only 2.8% of anti-malarialstocking general retailers had a first-line ACT available.
Chloroquine was most commonly available among drug
stores (20.5%), general retailers (67.1%), and itinerant
drug vendors (30.7%). Only one package of oral AMT
was found, and this product was audited at a general
retail outlet.
Market share

Figure 1 shows a detailed breakdown of the anti-malarial market share across sectors, outlet types, and antimalarial type. Most of the anti-malarials were sold or
distributed through the private sector (58.4%). Across the
private sector, most of the anti-malarial market share was
composed of private for-profit health facilities (26.7%)
and itinerant drug vendors (23.4%).
In terms of the types of anti-malarials being sold or
distributed, DHA PPQ contributed to the majority of
the market share in both the public and private sectors
(90.3% of the national market share). The private sector

67.7 (60.2, 74.3)
6.4 (4.1, 9.9)

69.7 (63.6, 75.1)
5.0 (3.2, 7.6)

anti-malarial market share was also composed of chloroquine (4.9%), which was primarily distributed through
private for-profit health facilities, general retailers, and
itinerant drug vendors.
Figure 2 shows a detailed breakdown of the diagnostic market share across sectors, outlet types, and diagnostic test type. The majority of the diagnostic market
share was composed of the private sector (57.6%), with
most diagnostic tests provided through private for-profit
health facilities (37.9%), itinerant drug vendors (9.1%),
and pharmacies (8.6%). Most diagnostic testing was performed using RDT rather than microscopy.
Private sector support

Table 5 shows a detailed breakdown of support reportedly received across private sector outlet types. Nearly
half of all interviewed outlets (44.4%) reported having
received any type of support. Nearly two-thirds of private for-profit health facilities (60.2%) and nearly threefourths of pharmacies (71.7%) reported having received
any type of support, while one in four itinerant drug vendors (25.5%) reported receiving any type of support.
Among outlets that reported receiving support, the
most common types of support reportedly received
were access to subsidized RDT (63.0%), training in the
past year on malaria diagnosis or the national treatment
guidelines for malaria (59.1%), and access to subsidized
anti-malarials (57.5%). Only 21.4% reported receiving a
supervisory or regulatory visit within the past year, and
36.9% reported keeping and reporting malaria caseload

ACTwatch Group et al. Malar J (2017) 16:171
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Table 4 Availability of malaria commodities in the private sector

Among all screened
outlets, availability of
Any anti-malarial
Among anti-malarialstocking outlets or
outlets stocking
anti-malarials in the
past 3 months, availability of

Private for-profit
health facility

Pharmacy

Drug store

General retailer Itinerant drug vendor All private sector

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

N = 668

N = 290

N = 338

N = 23,840

N = 924

N = 26,060

31.0 (26.1, 36.3)

20.5 (14.8, 27.6) 6.6 (4.2, 10.1)

0.2 (0.1, 0.4)

15.1 (11.4, 19.8)

1.8 (1.5, 2.1)

N = 237

N = 74

N = 39

N = 186

N = 570

83.0 (76.8, 87.8)

70.1 (58.2, 79.7) 60.9 (40.8, 77.9) 0.0 (–)

60.4 (50.6, 69.4)

64.7 (58.5, 70.3)

N = 34

Diagnostics
  Any malaria blood
testing
  Malaria microscopy

15.6 (10.9, 22.0)

4.8 (1.6, 13.1)

5.6 (3.2, 9.8)

8.7 (6.4, 11.9)

  RDT

81.3 (74.8, 86.5)

70.1 (58.2, 79.7) 60.9 (40.8, 77.9) 0.0 (–)

59.8 (50.0, 68.9)

63.8 (57.6, 69.6)

N = 186

N = 45

N = 109

N = 391

Among anti-malarial
stocking outlets, availability of

4.0 (0.6, 21.7)
N = 22

0.0 (–)
N = 29

Anti-malarials
  Any first-line ACT

90.0 (82.5, 94.5)

85.6 (74.3, 92.4) 47.9 (27.8, 68.6) 2.8 (0.5, 15.6)

62.8 (51.7, 72.7)

70.9 (63.1, 77.6)

  DHA PPQ

90.0 (82.5, 94.5)

85.6 (74.3, 92.4) 47.9 (27.8, 68.6) 2.8 (0.5, 15.6)

62.8 (51.7, 72.7)

70.9 (63.1, 77.6)

  ASMQ FDC

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

  Primaquine

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

  Chloroquine

4.6 (2.0, 10.3)

7.7 (2.9, 19.1)

20.5 (9.7, 38.1)

67.1 (27.6, 91.6)

30.7 (20.1, 43.7)

19.7 (14.1, 26.9)

  Other non-artemisinin therapy

1.3 (0.3, 5.4)

0.0 (–)

6.8 (1.9, 21.4)

0.0 (–)

1.8 (0.6, 5.2)

1.5 (0.7, 3.3)

  Oral AMT

0.0 (–)

0.0 (–)

0.0 (–)

2.3 (0.4, 12.7)

0.0 (–)

0.2 (0.0, 1.2)

  IV/IM artesunate

0.0 (–)

0.0 (–)

0.0 (–)

0.0 (–)

0.7 (0.1, 4.0)

0.2 (0.0, 1.3)

  Availability of
first-line ACT and
malaria blood
testing

80.4 (72.6, 86.3)

67.1 (52.5, 79.0) 23.6 (10.0, 46.1) 0.0 (–)

50.8 (40.2, 61.3)

59.4 (51.9, 66.6)

  Availability of firstline ACT, blood
testing not available

9.6 (6.1, 15.0)

18.5 (10.5, 30.5) 24.3 (9.4, 49.9)

12.0 (7.0, 19.9)

11.5 (8.4, 15.4)

data to either the government or a non-governmental
organization.
Figure 3 shows several key indicators showing antimalarial and diagnostic market availability, and provider
knowledge, according to outlet support status (the presence or absence of private sector support), while controlling for outlet type. Among private sector outlets stocking
any anti-malarial, the proportion of outlets with a firstline ACT was higher among outlets that had reportedly
received any type of support or engagement (hereinafter
referred to as ‘supported’ outlets) compared to outlets
that did not report receiving any support (82.1 and 60.6%,
respectively). Similar results were observed for availability of malaria blood testing, where 78.2% of supported

2.8 (0.5, 15.6)

outlets had a malaria blood test available compared to
64.0% of unsupported outlets. With regards to provider
knowledge, 80.2% of providers in supported outlets correctly stated the first-line treatment for uncomplicated
malaria (either DHA PPQ or ASMQ FDC) compared to
just 47.0% of providers in unsupported outlets. Finally,
supported outlets were less likely to be stocking an antimalarial not indicated in the national treatment guidelines for malaria compared to unsupported outlets (14.0%
compared to 43.0%, respectively).
Figure 4 shows median prices for malaria RDT and
DHA PPQ according to outlet support. Outlets that
reported having received any type of support reported
a median consumer price of $0.75 for a malaria RDT
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Fig. 2 Malaria confirmatory testing market share

compared to a median price of $1.49 in unsupported outlets. Similarly, the median price of one AETD of DHA
PPQ in supported outlets was $1.24 compared to $2.49 in
unsupported outlets.

diagnosis was commonplace—particularly in the public
sector. However, the data also highlight key gaps across
both sectors that must be addressed and which are discussed further in this section.

Discussion
The 2015 outlet survey findings provide contemporary
evidence on the availability and market share of malaria
commodities. Several positive outlet survey findings
regarding the readiness and performance of the public
and private sectors are observed: first-line ACT availability and distribution was widespread, and malaria

Public sector readiness to test and treat for malaria

Readiness to appropriately manage malaria cases, measured through availability of malaria blood testing and
a first-line ACT, was observed at only approximately
two-thirds of public health facilities, indicating that
around one in three public health facilities were lacking the capacity to both diagnose and appropriately
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Table 5 Percent of private sector outlets who reportedly received government or non-governmental support,
and among outlets who received a support strategy, type of support received
Private for-profit
health facility

Pharmacy

Drug store

General retailer Itinerant drug vendor All private sector

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

% (95% CI)

N = 326

N = 99

N = 46

N = 39

N = 235

N = 745

N = 196

N = 69

N = 19

N=1

N = 64

N = 349

Report access to subsidized anti-malarials

58.3 (49.2, 66.9)

69.4 (58.7, 78.5) 26.8 (13.3, 46.6) 0.0 (–)

55.7 (44.4, 66.5)

57.5 (51.1, 63.7)

Report access to subsidized RDT

63.5 (54.0, 72.1)

69.1 (58.9, 77.7) 60.2 (36.4, 80.0) 0.0 (–)

58.6 (45.5, 70.7)

63.0 (55.9, 69.6)

Report received train- 65.3 (57.1, 72.7)
ing in the past year
on malaria diagnosis
(RDT and/or microscopy) and/or the
National treatment
guidelines for malaria

66.0 (53.2, 76.8) 36.1 (18.0, 59.2) 100.0 (–)

42.6 (31.5, 54.4)

59.1 (53.9, 64.2)

Report receiving a
supervisory or regulatory visit within the
past year

27.6 (21.7, 34.3)

17.8 (8.9, 32.6)

20.7 (5.5, 54.0)

0.0 (–)

8.6 (3.9, 18.0)

21.4 (16.7, 27.0)

Report keeping and
reporting malaria
caseload data to
government or
non-government
organization

50.3 (40.0, 60.6)

22.2 (11.8, 37.9) 18.0 (4.0, 53.4)

0.0 (–)

21.1 (11.7, 35.0)

36.9 (27.8, 47.1)

Received any type of
support

60.2 (53.6, 66.4)

Among outlets with
support

71.7 (61.7, 80.0) 45.5 (29.7, 62.2) 3.2 (0.7, 13.8)

25.5 (18.8, 33.6)

44.4 (39.0, 49.9)

100
90

PERCENT OF OUTLETS

80
70
60
50
40
30
20
10
0

Stocking national first-line
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Malaria blood testing
available

Received at least one private sector support strategy
Fig. 3 Key indicators by private sector support status

Provider correctly stated Stocking any antimalarial not in
first-line treatment for national treatment guidelines for
uncomplicated malaria
uncomplicated malaria

Did not receive any private sector support
strategy

ACTwatch Group et al. Malar J (2017) 16:171

Page 12 of 16

$4.50

MEDIAN PRICE IN 2015 USD

$4.00
$3.50
$3.00

$2.49

$2.50
$2.00

$1.49

$1.50
$1.00

$1.24

$0.75

$0.50
$0.00

Received at least one private sector support
strategy

RDT

Did not receive any private sector support strategy

DHA PPQ

Fig. 4 Median consumer prices for adult RDT and DHA PPQ, by private sector support status

treat uncomplicated malaria. According to Cambodia’s
national treatment guidelines for malaria, and in order
to achieve the universal coverage strategy described in
the MEAF, all of the public sector outlet types must be
equipped to test for and treat uncomplicated malaria.
Moving forward, it will be critical to maintain a constant
supply of malaria commodities. At the time of this survey, the CNM was developing the Logistic Management
Information System (LMIS) to measure quantification,
long-lasting insecticide-treated net (LLIN) demand,
forecasting, and stock, with the aim of providing more
regular reports and thus reducing the frequency of stock
outs in the public sector [14]. The LMIS is expected to
ideally move the country towards universal coverage by
ensuring a constant supply of malaria commodities at all
public sector outlets. Indeed, findings from other countries have supported this prediction, demonstrating that
investments to strengthen management information systems can lend a more streamlined, demand-driven, and
accountable procurement and supply chain system [15].
The role of the private sector

The majority of private sector outlets screened were
not in the business of stocking malaria commodities,
with fewer than one in three private for-profit health
facilities and one in five pharmacies stocking an antimalarial. This reflects an overall decline in anti-malarial
availability among these private sector outlets in recent
years [5]. In 2015, malaria case management services in
the private sector were concentrated among private forprofit health facilities and pharmacies, which are the
only private sector outlet types authorized to distribute anti-malarial medicines [1]. The concentration of
malaria commodities among authorized outlet types may

reflect increased regulation of the private sector and/or
may also be a result of a decline in provider incentives to
stock anti-malarials, given declining burden and perhaps
less consumer demand for malaria treatment. However,
the relatively low availability of malaria commodities in
the private sector indicates that a febrile patient seeking
care in the private sector may have to approach multiple
facilities to find one with malaria testing and treatment.
This points to the importance of a referral system, such
as the Private Sector SMS Referral System piloted in 2012
by the CNM and partners [16], as well as a need to scale
up health services at the community level.
While most private sector outlets were not in the
business of malaria case management, results nonetheless show that the private sector was responsible for the
majority of anti-malarial distribution and malaria testing
provision. This finding is consistent with other research
in Cambodia and neighboring countries such as Lao
PDR and Myanmar [17, 18]. Market share data also illustrate that, while a large portion of the private sector case
management was channeled through private for-profit
health facilities and pharmacies, there was also a significant contribution from itinerant drug vendors—an illicit
and unregulated outlet type in Cambodia. Although itinerant drug vendors are not a formal or regulated outlet
type, provider demographic results show that approximately one in five itinerant drug vendors reported having completed university or college, and nearly two in
three itinerant drug vendors reported having a health
qualification, mostly as a nurse or nursing officer. This
suggests that these providers could be considered assets
in improving appropriate malaria case management
coverage, if they can be appropriately regulated and
supervised.
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The MEAF has outlined plans to target certain unlicensed providers and encourage them to obtain a licence
in order to join the PPM programme, and it also describes
goals to enforce existing laws that would prohibit operation of itinerant drug vendors. However, there may be
some benefit from further exploration into whether itinerant drug vendors could be effectively licensed and regulated under the PPM programme. Several studies have
documented success with the VMW programme [5, 19],
which has increased access to appropriate malaria case
management in many rural areas of Cambodia utilizing
people with overall less education and fewer baseline
health qualifications compared to itinerant drug vendors (Additional file 1). In sub-Saharan Africa, several
malaria-endemic countries have documented improvements in provider knowledge and performance after
implementation of strategies such as training and capacity-building, demand generation, quality assurance, and
creating an enabling environment, all of which targeted
the informal private sector, including itinerant drug vendors [20]. Furthermore, the WHO has recommended the
engagement of itinerant drug vendors, where appropriate, as a method of improving home-based management
of malaria [21, 22], and analyses by the U.S. Agency for
International Development (USAID) have also concluded
that policies through which national programmes engage
with private providers—both formal and informal—can
be beneficial to improving provision of care for malaria
and other important health issues in developing countries [23]. Extending permission to test for and treat
malaria to trained and supervised itinerant drug vendors
may be an important strategy in Cambodia to accelerate
universal coverage of confirmatory testing and appropriate malaria treatment and to continue expanding coverage to remote, rural populations.
Private sector readiness and performance

Where anti-malarials were available in the private sector,
the majority of anti-malarial stocking outlets had a firstline ACT available. However, nearly one in three private
sector outlets were not stocking a first-line ACT and
were primarily stocking chloroquine, which is no longer
indicated for use in the national treatment guidelines
for malaria. While the majority of anti-malarial-stocking private sector outlets had malaria diagnostic testing
available, approximately one in three did not have testing available. These gaps in private sector readiness are a
threat to appropriate management of suspected malaria
cases, as they demonstrate a potential for presumptive
anti-malarial treatment and/or treatment with medicines
that are not indicated in the national treatment guidelines for malaria.
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Most anti-malarials distributed by the private sector
were DHA PPQ, a first-line ACT. However, chloroquine
and artemisinin–piperaquine were also distributed in the
private sector, indicating that some private sector providers were not in full alignment with the national treatment
guidelines for malaria. Indeed, availability data show that
all private sector outlet types were found to be stocking chloroquine, with the highest availability observed
among general retailers. While availability and market
share of a first-line treatment were high among private
for-profit health facilities and pharmacies, chloroquine
stubbornly persists and most notably among itinerant drug vendors, pointing to the need to completely
remove this anti-malarial from the market. One strategy
by which to achieve this goal would be to ban the import
and sale of this anti-malarial, especially given evidence
that a similar ban on oral artemisinin monotherapy in
2008 was found to be a successful measure to remove this
anti-malarial from the market [5]. This is also addressed
in the MEAF strategy, which stipulates that there will
be increased efforts to ban the import and sale of antimalarial drugs not in national treatment guidelines for
malaria.
Private sector support

Results from this study showed that access to any supportive intervention—including subsidized anti-malarials or RDT, training, supervisory or regulatory visits,
or reporting caseload data—was associated with higher
availability of a first-line ACT, higher availability of
malaria testing, higher provider knowledge of first-line
treatment guidelines for malaria, and lower availability of
an anti-malarial not in the national treatment guidelines
for malaria. In addition, the study showed that private
sector outlets with access to any supportive intervention priced their malaria commodities lower than outlets
that did not have access to any supportive intervention,
meaning more affordable access to malaria testing and
treatment for consumers.
These results suggest that strategies such as subsidies,
training, and supervision can improve private sector
readiness and performance, as has been demonstrated in
other contexts [24]. However, this study was not designed
to evaluate specific types of private sector support, nor
was it able to compare the performance of PPM outlets
with non-PPM outlets. There is further need to examine
the outcomes associated with the various aspects of the
PPM programme to identify where there may be a need
to strengthen specific components. The extent to which
the measures of access to supportive interventions, as
outlined in this paper, can be used to inform specific
strategies relating to the PPM programme is limited.
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Results from this study reflect positively on the work
that has been done to-date in Cambodia to engage the
private sector. However, there is a need to increase coverage of private sector support and, in doing so, more
evidence about the performance of current strategies is
needed in order to facilitate efficient and effective progress in the private sector. As intended under the PPM
programme, current strategies appear to be reaching private health facilities and pharmacies to a much greater
extent than itinerant drug vendors. As noted above,
extending private sector support to itinerant drug vendors may be an important strategy for improving overall
private sector readiness and performance. In addition,
investigation into the merits of other types of private sector strategies, such as integration of RDT financial incentives and information, education, and counseling, may
be useful interventions as evidenced among the informal private sector in neighboring Myanmar [25]. Finally,
future research that specifically addresses the PPM
programme may be merited in order to better understand how this strategy has affected anti-malarial and
diagnostic market performance to date and in order to
more specifically inform policy decisions relating to this
programme.
Gaps in availability of ASMQ FDC and primaquine

In its continuing effort to keep one step ahead of drug
resistance, Cambodia’s national treatment guidelines for
malaria changed in 2014 in response to emerging resistance to DHA PPQ, such that ASMQ FDC is now recommended in geographic areas with DHQ PPQ failure.
As of June 2015, failure rates of DHA PPQ have reached
over 60% in certain areas of the country, pointing to the
immediate need to ensure access to ASMQ FDC [1].
During data collection for this survey, which took place
in August and September of 2015, ASMQ FDC was not
found. The absence of this anti-malarial in the market
may be due in part to a variety of challenges with manufacturing and procurement. Cambodia has faced procurement challenges in the past, most notably after the
switch in malaria treatment guidelines to DHA PPQ
in 2010, when a lack of suitable manufacturers led to a
significant delay and subsequent stock out of first-line
anti-malarials in both the public and private sectors
[5]. In light of the constantly changing epidemiology of
malaria in Cambodia and the Greater Mekong Subregion
(GMS) as a whole, it is important that the country is able
to respond quickly to changing treatment recommendations and thus avoid lags in the stocking of appropriate
treatments. One option to consider are parallel procurement systems whereby two or more types of anti-malarial are stocked in-country to guarantee the availability
of an appropriate anti-malarial depending on the drug
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resistance, while accepting that drug wastage will be an
inevitable reality in the drive toward elimination [5].
Other considerations may include investment into a
centralized procurement system, with trained personnel, storage capacity, infrastructure and IT enablement
in order to forecast stock and supply, and distribution of
sufficient quantities of anti-malarials with minimal delays
[26]. In addition, any identification of treatment failure
should signal the need to start immediately forecasting
sufficient stock for new first-line treatments.
The MEAF and the national treatment guidelines for
malaria stipulate the use of primaquine to prevent P. falciparum transmission and P. vivax relapse, indicating
that it should be provided along with a first-line ACT for
both types of malaria. This study found that primaquine
was universally unavailable at the time of the survey.
This may reflect hesitancy to operationalize the use of
primaquine without a feasible way to test first for G6PD
deficiency [27]. However, WHO recommendations and
supporting publications demonstrate that a low dose
of primaquine can be safely administered regardless of
G6PD status [28–30]. As Cambodia scales up access to
primaquine, approaches used in neighboring countries
such as Myanmar, Thailand, and Vietnam may be useful to consider, as governments have limited the use of
primaquine to facilities that are equipped to either test
and/or monitor for signs of G6PD deficiency. However, it
should be noted that outlet survey evidence from Myanmar and Thailand illustrates that primaquine availability
in these facilities was generally lower compared to other
first-line treatments for uncomplicated malaria [31]. This
suggests that there may be issues in maintaining constant
supply or may demonstrate concerns by the governments
that facilities are not adequately equipped to either test
and/or monitor for signs of G6PD deficiency. Building on evidence from other countries that have historically included and implemented the use of primaquine
in their treatment policy will be helpful to facilitate full
implementation of the national treatment guidelines for
malaria in Cambodia.
Limitations

Despite its many strengths, the ACTwatch outlet survey has several limitations which have been described in
detail elsewhere [8, 32]. Notably, the survey had a cross
sectional design, which limits the conclusions that can be
drawn about causality as it relates to access to supportive
interventions and performance indicators in the private
sector. It is also acknowledged that, due to increased regulation of the private sector, especially as it relates to the
stocking of oral artemisinin monotherapy, providers may
have a disincentive to accurately report certain information, such as the stocking of artemisinin monotherapy or
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the stocking of any malaria commodities in outlets which
were unlicensed.

Conclusions
As Cambodia steps into an era of malaria elimination,
evidence on the availability and distribution of first-line
treatment for malaria and malaria diagnostic testing in
the public and private sectors is critical. Evidence from
the last ACTwatch outlet survey implemented in 2015
illustrates that there is a strong foundation for meeting
national malaria elimination goals: first-line ACT availability and distribution was widespread, and malaria
diagnosis was commonplace—particularly in the public sector. This evidence can serve as a benchmark for
guiding the implementation of strategies outlined in the
MEAF as well as other regional initiatives to address
elimination activities. The private sector remains responsible for the majority of malaria testing and treatment
in Cambodia, indicating that strategies to effectively
support the private sector are critical to continued progress. Identifying other regulatory strategies or supportive interventions to address anti-malarial availability and
distribution by unauthorized itinerant drug vendors is
needed.
Additional file
Additional file 1. Demographic information of private sector providers,
by outlet type.
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